Table 1.

Effect Sizes in Pharmacogenetic and Nonpharmacogenetic Phase ll AUD Treatment Trials

	Effect Size
Medication and End-point Variable	Nonpharmacogenetic Trials	Pharmacogenetic Trials Effect Size (Gene Tested)
Naltrexone
Relapse to heavy drinking	0.247 (Del Re et al. 2013)
Percent days abstinent	0.143 (Del Re et al. 2013)
Good clinical outcome	Not measured	>0.8 in carriers of rs1799971:G allele (Anton et al. 2008)
Ondansetron
Drinks per drinking day	NS; ondansetron vs. placebo main effects (Correa et al. 2013; Johnson et al. 2000, 2011)	0.87 in carriers of any one or more of the following genotypes → rs1150226:AG, rs1176713:GG, and rs17614942:AC; 0.59 when carriers of SLC6A4:LL and rs1042173: TT are added to the above group (Johnson et al. 2013)
% heavy drinking days	NS; ondansetron vs. placebo main effects (Correa et al. 2013; Johnson et al. 2000, 2011)	0.78 in carriers of any one or more of the following genotypes → rs1150226:AG, rs1176713:GG, and rs17614942:A; 0.42 when carriers of SLC6A4:LL and rs1042173: TT are added to the above group (Johnson et al. 2013)
% abstinent days	NS; ondansetron vs. placebo main effects (Correa et al. 2013; Johnson et al. 2000, 2011)	0.68 in carriers of any one or more of the following genotypes → rs1150226:AG, rs1176713:GG, and rs17614942:AC; 0.43 when carriers of SLC6A4:LL and rs1042173: TT are added to the above group (Johnson et al. 2013)
Topiramate
Drinks per drinking day	0.45 (Johnson et al. 2003, 2007a; Rubio et al. 2009)
% heavy drinking days	0.62 (Johnson et al. 2003, 2007a; Kranzler et al. 2014; Rubio et al. 2009)	Effective only in rs2832407:CC carriers but not in carriers of rs2832407:AC/AA (Kranzler et al. 2014)
% abstinent days	0.46 (Johnson et al. 2003, 2007a; Kranzler et al. 2014; Rubio et al. 2009)	Effective only in rs2832407:CC carriers but not in carriers of rs2832407:AC/AA (Kranzler et al. 2014)

All effect sizes are given in Cohen’s d. NS: Nonsignificant.